Market research
ANVS Annovis Bio Inc
NYSE USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 78M
- P/E ratio
- Not available
- Analyst target
- 11
- Dividend yield
- Not available
- Beta
- 1.24
Profile
Company facts
- Exchange
- NYSE
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US03615A1088
- Market cap
- 78M
- P/E ratio
- Not available
- Analyst target
- 11
- Dividend yield
- Not available
- Beta
- 1.24
About
About Annovis Bio Inc
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ANVS discussion.
5 years, 4 months ago
Annovis Bio, Inc is currently in a long term uptrend where the price is trading 319.8% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Annovis Bio, Inc gets an overall score of 2/5.